# Therapeutic Merit of Solifenacin in the Mitigation of Ureteral Stent-induced Pain and Lower Urinary Tract Symptoms

> **NCT01381120** · PHASE4 · COMPLETED · sponsor: **Barrie Urology Associates** · enrollment: 84 (actual)

## Conditions studied

- Flank Pain
- Urinary Bladder, Overactive

## Interventions

- **DRUG:** Solifenacin succinate treatment
- **DRUG:** Oxycodone and acetaminophen combination treatment

## Key facts

- **NCT ID:** NCT01381120
- **Lead sponsor:** Barrie Urology Associates
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2012-08-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01381120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01381120, "Therapeutic Merit of Solifenacin in the Mitigation of Ureteral Stent-induced Pain and Lower Urinary Tract Symptoms". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT01381120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*